Dose Cancer Research Results

Dose, Dosage: Click to Expand ⟱
Source:
Type:
Drug dosage vs efficacy, and actual dosage number of research papers.
NSCLC, Non-small Cell Lung Cancer: Click to Expand ⟱
Non-small Cell Lung Cancer
Scientific Papers found: Click to Expand⟱
257- AL,  Cisplatin,    Allicin Overcomes Hypoxia Mediated Cisplatin Resistance in Lung Cancer Cells through ROS Mediated Cell Death Pathway and by Suppressing Hypoxia Inducible Factors
- in-vitro, NSCLC, A549
ROS↑, HIF-1↓, E-cadherin↑, N-cadherin↓, antiOx↓, Dose↝,
5361- almon,    Abstract CT190: A multicenter, open-label, single-arm, phase II study: The third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO)
- Trial, NSCLC, NA
EGFR↓, OS↑, Dose↝,
5360- almon,  BEV,    Case report: Almonertinib in combination with bevacizumab for leptomeningeal metastases from epidermal growth factor receptor-mutation non-small cell lung cancer: Case series
- Case Report, NSCLC, NA
BBB↑, Dose↝, eff↓, OS↑,
5716- BF,    Pilot Study of Huachansu in Patients with Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, or Pancreatic Cancer
- Trial, NSCLC, NA - Trial, PC, NA - Trial, HCC, NA
Dose↝, toxicity↓, other↓, QoL↑, OS?,
6548- BSB,    Anticancer effects of α-Bisabolol in human non-small cell lung carcinoma cells are mediated via apoptosis induction, cell cycle arrest, inhibition of cell migration and invasion and upregulation of P13K/AKT signalling pathway
- in-vitro, NSCLC, A549
AntiCan↑, Dose↝, TumCCA↑, mt-Apoptosis↑, TumCMig↓, PI3K↓, Akt↓,
6969- Form,    Formononetin inhibits tumor growth by suppression of EGFR-Akt-Mcl-1 axis in non-small cell lung cancer
- vitro+vivo, NSCLC, HCC827 - in-vitro, NSCLC, A549 - in-vitro, Lung, H1299
EGFR↓, Akt↓, GSK‐3β↑, TumCG↓, ChemoSen↑, Mcl-1↓, RadioS↑, tumCV↓, selectivity↑, Dose↝, Cyt‑c↑, BAX↑, Apoptosis↑, Ki-67↓, toxicity↓, chemoPv↑,
7136- GI,    [6]-shogaol inhibits growth and induces apoptosis of non-small cell lung cancer cells by directly regulating Akt1/2
- vitro+vivo, NSCLC, H1650
TumCP↓, TumCCA↑, Apoptosis↑, Akt↓, EGFR↓, STAT3↓, cycD1/CCND1↓, Casp3↑, Casp7↑, TumCG↓, Ki-67↓, eff↑, Dose↝,
7989- itraC,    Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer
- Trial, NSCLC, NA
Dose↝, TumVol↓, angioG↓, IL1β↓, GM-CSF↓, HH∅, BioAv↝, other↝,
8126- LF,    Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy
- NA, NSCLC, NA
Dose↝, OS↑, PFS↑, DCR↑, other↝,
6431- T4O,    Terpinen-4-ol Induces Apoptosis in Human Nonsmall Cell Lung Cancer In Vitro and In Vivo
- vitro+vivo, NSCLC, A549
TumCCA↑, Casp3↑, Casp9↑, cl‑PARP↑, MMP↓, Bax:Bcl2↑, XIAP↓, survivin↓, Dose↝, Apoptosis↑, tumCV↓, Cyt‑c↑, eff↑, necrosis↑,

Showing Research Papers: 1 to 10 of 10

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 10

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

DCR↑, 1,   PFS↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   ROS↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 1,   XIAP↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 3,   Apoptosis↑, 3,   mt-Apoptosis↑, 1,   BAX↑, 1,   Bax:Bcl2↑, 1,   Casp3↑, 2,   Casp7↑, 1,   Casp9↑, 1,   Cyt‑c↑, 2,   Mcl-1↓, 1,   necrosis↑, 1,   survivin↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↓, 1,   other↝, 2,   tumCV↓, 2,  

DNA Damage & Repair(tgid=10) ⓘ

cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

GSK‐3β↑, 1,   HH∅, 1,   PI3K↓, 1,   STAT3↓, 1,   TumCG↓, 2,  

Migration(tgid=13) ⓘ

E-cadherin↑, 1,   Ki-67↓, 2,   N-cadherin↓, 1,   TumCMig↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   EGFR↓, 3,   HIF-1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

GM-CSF↓, 1,   IL1β↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 1,   ChemoSen↑, 1,   Dose↝, 10,   eff↓, 1,   eff↑, 2,   RadioS↑, 1,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 3,   Ki-67↓, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   chemoPv↑, 1,   OS?, 1,   OS↑, 3,   QoL↑, 1,   toxicity↓, 2,   TumVol↓, 1,  
Total Targets: 56

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Dose, Dosage
2 almonertinib
1 Allicin (mainly Garlic)
1 Cisplatin
1 Bevacizumab (brand Avastin)
1 Bufalin/Huachansu
1 α-Bisabolol / Chamomile oil
1 Formononetin
1 Ginger/6-Shogaol/Gingerol
1 itraconazole
1 Lactoferrin/Talactoferrin
1 Terpinen-4-ol / Tea Tree Oil
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:19  Cells:%  prod#:%  Target#:1114  State#:%  Dir#:4
  wNotes=0  sortOrder:rid,rpid

 

Home Page